the publisher
About Doctor BPC-157
A close, cited reading of the BPC-157 research literature — what the studies established, where the human evidence stops, and how access stands.
What this scriptorium is
Think of Doctor BPC-157 as a scriptorium — a room where the peer-reviewed work on this pentadecapeptide is copied out by hand, glossed in the margins, and traced back to its source. Every page here is a reading of published science, and nothing more. There is no examining room behind it, no one on staff who prescribes or diagnoses, and no shelf of product to sell you; what the scriptorium offers is an attentive, sourced account of the record, and the plainness to say where that record thins.
It exists because most of what circulates online about BPC-157 is anecdote, sales copy, or both, while the actual literature — a large preclinical record, a coherent angiogenesis mechanism, and three small human pilots — deserves a careful, cited reading. We treat each finding the way an illuminated manuscript treats a passage: as something to read slowly, with its source named, rather than something to skim.
Why "Doctor" is on the door
The "doctor" in Doctor BPC-157 names a reading posture, not a service. It marks the register this scriptorium works in — literature read closely, weighed, annotated — the way a learned reader once sat with a difficult text. It is not shorthand for a practice you can visit. No one here will see you, examine you, or write you anything; there is no clinical staff and no consultation to book. The word describes how we approach the research, and stops there.
We spell this out because the distance between a room that only reads the science and a clinic that offers treatment is exactly the distance a reader should keep in mind when the subject is an unapproved research peptide.
How we handle evidence
Every number that appears here — each dose, percentage, half-life, and sample size — is tied to a numbered entry on the BPC-157 references page, pulled from PubMed, peer-reviewed journals, and FDA's own pages. We set down what was given to which species, at which dose, by which route; we recommend no dose for a person, and we report the human evidence as the three small pilots it is. Where the record runs thin, we mark the gap rather than fill it with inference.
We lead with findings and attribute them, and we keep the safety caveats — the overwhelmingly preclinical evidence, the single-investigator-source question, the unknown long-term oncologic picture, the regulatory status — in plain view. The aim is a reading you can trust precisely because it does not oversell.